FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1340-1342 November 1, 2001 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Eriksson, B. I. Related Article by Bauer, K. A. PubMed Citation

For decades, if a patient required a parenteral anticoagulant agent, the choice was simple: unfractionated heparin was the only such agent available. Unfractionated heparin has a long track record of effectiveness in both the treatment of and prophylaxis against arterial and venous thromboembolic disease. However, because of differences among batches of heparin and problems related to the bioavailability of the drug, monitoring of the anticoagulant effect of heparin has been not only necessary but also problematic. In addition, heparin-induced bleeding and thrombocytopenia can threaten life and limb. Moreover, there have always been problems with the use of unfractionated heparin to . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Tran, A. H, Lee, G. (2003). Fondaparinux for Prevention of Venous Thromboembolism in Major Orthopedic Surgery. The Annals of Pharmacotherapy 37: 1632-1643 [Abstract] [Full Text]  
• Bates, S. M., Weitz, J. I. (2003). Emerging Anticoagulant Drugs. Arterioscler. Thromb. Vasc. Bio. 23: 1491-1500 [Abstract] [Full Text]  
• Murashige, N., Kami, M., Marlovits, S., Priestley, M., Scacewater, R., Eriksson, B. I., Diuguid, D. L. (2002). Prevention of Venous Thromboembolism with Fondaparinux. NEJM 346: 940-942 [Full Text]  
• (2001). More Data on a New Antithrombotic Drug. JWatch General 2001: 3-3 [Full Text]